An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy Clinical Trial

Official title: An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy

Status Terminated

Clinical Trial Summary

The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy. Also, the effects of UCB0942 on the patient's quality of life will be explored.

Clinical Trial Description

For those subjects who benefit substantially from UCB0942 in the multicenter, randomized, double-blind, placebo-controlled, parallel group study EP0069, the current open-label extension study EP0073 will provide an opportunity to continue UCB0942 treatment after a careful evaluation of the individual benefit-risk balance and with close monitoring of safety, tolerability and efficacy of long-term study treatment. ;

Related Conditions & MeSH terms

• Epilepsies, Partial
• Epilepsy
• Highly Drug-resistant Focal Epilepsy

• NCT number: NCT02625090
• Study type: Interventional
• Source: UCB Pharma
• Status: Terminated
• Phase: Phase 2
• Start date: December 3, 2015
• Completion date: November 24, 2020